Kyowa Hakko Kirin Commences Phase I/II U.S. Trial For Breast Cancer Drug
This article was originally published in PharmAsia News
Executive Summary
Kyowa Hakko Kirin has started a Phase I/II study for breast cancer drug candidate KW-2450 in the U.S